OneWorld Health completes enrollment, treatment in Phase III I...( San Francisco Calif. May 18 2004 Th...)

San Francisco, Calif. May 18, 2004 The Institute for OneWorld Health, the first nonprofit pharmaceutical company in the U.S., announced today it has completed enrollment and treatment of 667 patients in India suffering from visceral leishmaniasis (VL), a deadly parasitic disease also known as kala azar. Funded largely by the Bill & Melinda Gates Foundation, the largest Phase III clinical trial for VL will conclude with final follow-up patient exams in November. The approval application to use paromomycin will be submitted in early 2005 to the government of India.

Transmitted by the bite of a sand fly, VL is a deadly vector (insect)-borne disease that attacks the internal organs. An estimated 1.5 million people worldwide are currently infected; 200 million people are at risk of acquiring VL; and as many as 200,000 people die annually. Left untreated, it is fatal. With the exception of malaria, VL kills more people than any other parasitic disease. While most Westerners have never heard of visceral leishmaniasis, if the disease existed in the U.S., it would be the third largest killer after heart disease and cancer, and would cause more deaths than stroke.

OneWorld Health is developing the injectable form of paromomycin as a 21-day cure for VL. The drug is an off-patent antibiotic which was previously approved by the U.S. FDA and is still marketed in the U.S. as an oral formulation to treat intestinal parasites. Last June, OneWorld Health initiated the Phase III clinical trial in Bihar, India, in collaboration with the Special Programme for Research and Training in Tropical Diseases of the World Health Organization (WHO/TDR).

"We are very encouraged by initial trial results," said Victoria Hale, Ph.D., CEO of OneWorld Health. "The advantage of finding new uses for existing drugs means people who need affordable medicines the most will benefit sooner, given the wealth of existing safety and efficacy data."

OneWorld Health's leade
'"/>

Contact: Joanne Hasegawa
jhasegawa@oneworldhealth.org
415-421-4700
Institute for OneWorld Health
18-May-2004

Page: 1 2
Related biology news :

1. OneWorld Health compiles comprehensive state of infectious diarrhea treatments, potential solutions
2. Institute for OneWorld Health nominated for the 2004 World Technology Awards
3. Institute for OneWorld Health receives Gates Foundation grant
4. OneWorld Health CEO outlines mutually beneficial collaborations between industry, nonprofits at BIO
5. Institute for OneWorld Health CEO to speak at BIO on leveraging opportunities for global health
6. Institute for OneWorld Health CEO advocates focus first on developing world markets
7. OneWorld Health plans to form network of volunteer pharmaceutical scientists for global health
8. UC Santa Barbara donates discovery to OneWorld Health that may speed disease treatment
9. Victoria Hale of Institute for OneWorld Health Named Fellow by International Womens Forum
10. Health of worlds sea lions the focus of Wakefield Symposium
11. Healthy fats and oils essential to satisfy calorie-conscious consumers